Literature DB >> 19662377

The longest ever randomised controlled trial of insulin glargine: study design and HbA(1c) findings.

C J Currie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19662377     DOI： 10.1007/s00125-009-1477-6

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  4 in total

1.  Does diabetes therapy influence the risk of cancer?

Authors:  U Smith; E A M Gale
Journal:  Diabetologia       Date:  2009-09       Impact factor: 10.122

2.  The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.

Authors:  C J Currie; C D Poole; E A M Gale
Journal:  Diabetologia       Date:  2009-07-02       Impact factor: 10.122

3.  Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study.

Authors:  J Rosenstock; V Fonseca; J B McGill; M Riddle; J P Hallé; I Hramiak; P Johnston; M Davis
Journal:  Diabetologia       Date:  2009-07-16       Impact factor: 10.122

4.  Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.

Authors:  J Rosenstock; V Fonseca; J B McGill; M Riddle; J-P Hallé; I Hramiak; P Johnston; M Davis
Journal:  Diabetologia       Date:  2009-06-13       Impact factor: 10.122
  4 in total
  5 in total

1.  Diabetes and cancer: a consensus report.

Authors:  Edward Giovannucci; David M Harlan; Michael C Archer; Richard M Bergenstal; Susan M Gapstur; Laurel A Habel; Michael Pollak; Judith G Regensteiner; Douglas Yee
Journal:  Diabetes Care       Date:  2010-07       Impact factor: 19.112

2.  (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.

Authors:  Thomas Semlitsch; Jennifer Engler; Andrea Siebenhofer; Klaus Jeitler; Andrea Berghold; Karl Horvath
Journal:  Cochrane Database Syst Rev       Date:  2020-11-09

3.  Looking at the carcinogenicity of human insulin analogues via the intrinsic disorder prism.

Authors:  Elrashdy M Redwan; Moustafa H Linjawi; Vladimir N Uversky
Journal:  Sci Rep       Date:  2016-03-17       Impact factor: 4.379

Review 4.  Insulin Resistance: Any Role in the Changing Epidemiology of Thyroid Cancer?

Authors:  Roberta Malaguarnera; Veronica Vella; Maria Luisa Nicolosi; Antonino Belfiore
Journal:  Front Endocrinol (Lausanne)       Date:  2017-11-14       Impact factor: 5.555

Review 5.  Diabetes Mellitus and Risk of Hepatocellular Carcinoma.

Authors:  Xu Li; Xiaocong Wang; Pujun Gao
Journal:  Biomed Res Int       Date:  2017-12-12       Impact factor: 3.411
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.